Simultaneous inhibition of XIAP and survivin expression on EMT and invasion of human pancreatic cancer cells

Journal of Central South University (Medical Sciences)

Volumn 37, Issue 9, 2012, Pages 883-888

  Zai, Hongyan ^a   Yi, Xiaoping ^a   Li, Yixiong ^a   Jiang, Chun ^a   Lü, Xinsheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition (EMT); Inhibitor of apoptosis proteins (IAPs); Invasive; Pancreatic cancer; PTEN PI3K Akt

Indexed keywords

BIRC5 PROTEIN, HUMAN; CADHERIN; CDH1 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84869198393     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2012.09.004     Document Type: Article

References (22)

1. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views[J]. J Pathol, 2008, 214(3):283-293. (Pubitemid 351212383)
2. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway[J]. Cancer Res, 2009, 69(6):2400-2407.
3. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells[J]. Ann Surg Oncol, 2007, 14(12):3629-3637. (Pubitemid 350160137)
4. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer[J]. Cancer Res, 2009, 69(14):S820-S828.
5. Li Y, Van den Boom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells[J]. Cancer Res, 2009, 69(16):6704-6712.
6. ZAI Hongyan, JIANG Chun, YI Xiaoping, et al. Influence of stable inhibition of XIAP and survivin expression on biological characteristics of pancreatic cancer cells[J]. Chinese Journal of General Surgery, 2012, 21(3):304-311.
7. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance[J]. Cancer Sci, 2010, 101(2):293-299.
8. Srivastava RK, Tang SN, Zhu W, et al. Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells[J]. Front Biosci (Elite Ed), 2011, 3:51S-S28.
9. Tang SN, Fu J, Nail D, et al. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics[J]. Int J Cancer, 2011, 131(1):30-40.
10. Shankar S, Nail D, Tang SN, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelialmesenchymal transition[J]. PLoS One, 2011, 6(1):e16S30.
11. Du Z, Qin R, Wei C, et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells[J]. Dig Dis Sci, 2011, 56(3):741-750.
12. Min C, Eddy SF, Sherr DH, et al. NF-kappaB and epithelial to mesenchymal transition of cancer[J]. J Cell Biochem, 2008, 104(3):733-744. (Pubitemid 351830825)
13. Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion[J]. Proc Natl Acad Sci USA, 2008, 105(17):6392-6397. (Pubitemid 351758356)
14. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications[J]. Curr Cancer Drug Targets, 2008, 8(3):187-198. (Pubitemid 351688437)
15. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer[J]. Apoptosis, 2004, 9(6):667-676. (Pubitemid 40941196)
16. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma[J]. Cancer Res, 2006, 66(24):11613-11622. (Pubitemid 46094172)
17. Ng SSW, Tsao MS, Chow S, et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells[J]. Cancer Res, 2000, 60(19):5451-5455.
18. Sourbier C, Lindner V, Lang H, et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy[J]. Cancer Res, 2006, 66(10):5130-5142. (Pubitemid 43844935)
19. Andersson R, Aho U, Nilsson BI, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions [J]. Scand J Gastroenterol, 2009, 44(7):782-786.
20. Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players[J]. Clin Cancer Res, 2008, 14(5):1284-1285. (Pubitemid 351413904)
21. Park Y, Kang MH, Seo HY, et al. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression[J]. Med Oncol, 2010, 27(4):1192-1199.
22. Chen X, Liao J, Lu Y, et al. Activation of the PI3K/Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells Panc-1 [J]. Pathol Oncol Res, 2011, 17(2):257-261.